AE-941 (Neovastat) versus placebo in metastatic renal cell carcinoma patients who are refractory to immunotherapy
Phase of Trial: Phase III
Latest Information Update: 04 Mar 2013
At a glance
- Drugs AE 941 (Primary)
- Indications Renal cell carcinoma
- Focus Registrational; Therapeutic Use
- Sponsors AEterna Zentaris Inc
- 07 Feb 2008 Status changed from in progres to completed.
- 27 Dec 2007 New trial record.
- 24 Sep 2003 Primary endpoint 'Survival' has not been met.